Latest Adenocarcinoma Stories
Preclinical Data Indicates Targeting Hyaluronan in the Tumor Stroma May Offer A New Approach to Pancreatic Cancer Treatment SAN DIEGO, Oct.
Enables physicians to pursue more effective treatment plans for patients who are chemoradiation resistant CHICAGO, May 6, 2014 /PRNewswire/ -- Castle Biosciences Inc.
DALLAS, April 26, 2014 /PRNewswire/ -- RnRMarketResearch.com offers Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows
A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type’s molecular idiosyncrasies.
Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells – a specific genetic weakness that can be exploited for new therapies.
A diagnosis of pancreatic cancer is particularly devastating since the prognosis for recovery is usually poor, with the cancer most often not detected until late stages.
The global "epidemic" of one type of gullet cancer (adenocarcinoma) seems to have started in the UK during the 1950s, sparked by some as yet unknown, but common, factor.
Investigators at the University of Texas MD Anderson Cancer Center, Houston, have reported on a new approach to treating previously inoperable complex pancreatic adenocarcinoma that has significantly increased long-term survival for some patients.
Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.